PremiumThe FlyThe biopharmaceuticals stocks to own in 2024, according to BofA Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited Karuna Therapeutics price target raised to $330 from $197 at UBS PremiumThe FlyKaruna deal favorable for Axsome Therapeutics, says H.C. Wainwright Reviva may be most undervalued in neurology, says H.C. Wainwright Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright PremiumThe FlyKaruna Therapeutics downgraded to Hold from Buy at Maxim Karuna Therapeutics downgraded to Market Perform from Outperform at William Blair Karuna Therapeutics downgraded to Sector Perform from Outperform at RBC Capital 
